Acura Pharmaceuticals, Inc: Schutte John Opened Position

August 3, 2017 - By Hazel Jackson

 Acura Pharmaceuticals, Inc: Schutte John Opened Position

The New Schutte John Holding in Acura Pharmaceuticals, Inc

Schutte John reported SC 13D form with the SEC for Acura Pharmaceuticals, Inc. Access it here: 000114420417040198. As reported by Schutte John, the filler owns 47.5% or 10,695,186 shares of the Health Care–company.

Acura Pharmaceuticals, Inc stake is new for [reportingPerson]. Date of activity: July 24, 2017. This shows Schutte John’s positive view for Acura Pharmaceuticals, Inc.

Reasons Why Schutte John Bought – Acura Pharmaceuticals, Inc Stock

Item 4. Purpose of Transaction

Mr. Schutte is ownerof Mainpointe Pharmaceuticals, LLC, which acquired two products from the Issuer in March 2017 and has options on several otherproducts.

The purpose of thetransaction was to provide funding to the Company so that it could continue to develop its LimitX™ technology and enhanceits Impede® technology of which MainPointe Pharmaceuticals, LLC is a licensee.

In connection withthe purchase of securities, Mr. Schutte entered into a voting agreement pursuant to which he is entitled to designate a directorto the Board of Directors and to committees thereof and pursuant to which he is required to vote for the designees of two otherentities and the Chief Executive Officer as directors.

Mr. Schutte seeks toenhance the value of the Company. However, he has not formulated definitive plans.

Mr, Schutte may purchaseadditional shares of the Issuer in the immediate future; however, he presently has no intention to substantially increase his ownershipin the Issuer.

In addition, underappropriate circumstances Mr. Schutte may support a sale of the Company or a merger with another entity.

CUSIP No. 00509L80213DPage 4 of 7

Except as describedabove, Mr. Schutte does not have any plans or proposals which relate to or would result in:

(1)theacquisition by any person of additional securities of the Company or the disposition of additional securities of the Company;

(2)anextraordinary corporate transaction such as a merger, reorganization or liquidation of the Company, involving the Company or anyof its subsidiaries;

(3)thesale or transfer of a material amount of assets of the Company or any of its subsidiaries;

(4)anychange in the present board of directors or management of the Company;

(5)anymaterial change in the Company’s present capitalization or dividend policy;

(6)anyother material change in the Company’s business or corporate structure;

(7)changesin the Company’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition ofcontrol of the Company by any person;

(8)causinga class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quotedin an inter-dealer quotation system of a registered national securities association;

(9)aclass of securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(10)anyaction similar to any of those enumerated above.

Business Profile

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

SEC Form 13D.

Wall Street await Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) to release earnings on August, 14. Analysts forecast EPS of $-0.11, up exactly $0.17 or 60.71 % from 2014’s $-0.28 EPS. After posting $0.03 EPS for the previous quarter, Acura Pharmaceuticals, Inc.’s analysts now forecast -466.67 % negative EPS growth.

About 240 shares traded. Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) has 0.00% since August 3, 2016 and is . It has underperformed by 16.70% the S&P500.

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The company has market cap of $5.35 million. The Firm is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. It currently has negative earnings. The Firm has discovered and developed three platform technologies, which can be used to develop multiple products.

More notable recent Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) news were published by: Nasdaq.com which released: “Acura Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference …” on August 03, 2017, also Gurufocus.com with their article: “Essex Woodlands Health Ventures, Inc. Buys Acura Pharmaceuticals” published on March 07, 2017, Seekingalpha.com published: “Acura Pharmaceuticals Seeks To Raise $5 Million In Offering” on February 07, 2017. More interesting news about Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) were released by: Seekingalpha.com and their article: “Acura Pharmaceuticals Is Grossly Undervalued And Poised For Rapid Growth” published on May 17, 2013 as well as Globenewswire.com‘s news article titled: “Acura Pharmaceutical Initiates Second Clinical Study on LTX-04” with publication date: May 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.